Clinical Trials
31 trialsNCT07164313 2026-05-07
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT06790966 2026-04-06
VERSATILE-003
PDS Biotechnology Corp.
Phase 3 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT04180215 2025-09-15
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Hookipa Biotech GmbH
Phase 1/2 Completed
NCT06771674 2025-09-09
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Completed
NCT06398418 2025-09-04
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics LLC
Phase 1 Recruiting
NCT06654999 2025-07-09
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
Skin Analytics Limited
Completed
NCT06513884 2025-06-22
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
Hookipa Biotech GmbH
Phase 2/3 Withdrawn
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT02164461 2024-05-20
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Phase 1 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05932511 2023-08-30
Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
Center for Biomedical Research, Inc.
Phase EARLY_PHASE1 Unknown
NCT00542308 2023-08-03
Zalutumumab in Non-curable Patients With SCCHN
Genmab
Phase 2 Completed
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT01234480 2023-05-16
Intended Use Study of the BD SurePath Plusâ„¢ Pap
Becton, Dickinson and Company
Terminated
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03817567 2019-01-25
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
Sinocelltech Ltd.
Phase 1/2 Unknown
NCT01142869 2017-05-08
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Merck KGaA, Darmstadt, Germany
Terminated
NCT00272181 2015-12-23
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
Sesen Bio, Inc.
Phase 2 Terminated
NCT00412776 2015-12-23
Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
Sesen Bio, Inc.
Phase 2/3 Terminated
NCT01075828 2014-08-29
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Merck KGaA, Darmstadt, Germany
Completed
NCT01075841 2014-07-02
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Merck KGaA, Darmstadt, Germany
Withdrawn
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00382031 2013-10-15
Zalutumumab in Patients With Non-curable Head and Neck Cancer
Genmab
Phase 3 Completed
NCT01283906 2013-09-12
MuGard
Access Pharmaceuticals, Inc.
Phase 4 Completed
NCT00401401 2011-12-23
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Genmab
Phase 1/2 Terminated
NCT00229723 2009-08-04
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00255476 2009-04-23
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
AstraZeneca
Phase 2 Completed